Business Wire

IQM Continues Its European Expansion; New French Subsidiary Will Focus on IQM’s Co-design Customers in Aviation, Space, and Cybersecurity.

Share

IQM France will collaborate closely with customers in the aviation, space, and cybersecurity verticals using IQM’s co-design approach. IQM is also part of Atos’s Scaler program, and this subsidiary will focus further on HPC integration and offer quantum accelerators to supercomputing centers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005096/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IQM Quantum Computers (Photo: Business Wire)

Through this new subsidiary, IQM joins the French quantum ecosystem that consists of world-renowned universities and research institutes and a fast-growing start-up scene and provides excellent industry infrastructure. IQM’s expertise and reach, combined with this vibrant ecosystem, will create significant opportunities for partnerships and collaboration in Europe and across the globe.

In the first phase, IQM France aims to tap into the extended talent pool of quantum students, postdocs, and experienced professionals. The plan is to start with a core team of business developers, products managers, quantum scientists, and engineers in 2022. The aim is to create a center of excellence in specific industry verticals and systematically grow in subsequent years.

IQM France’s office will be in the central hub at Spaces Les Halles on 40 rue du Louvre, Paris. Dr. Björn Pötter will take on the role of Country Manager for France in addition to his role as Global Head of Products at IQM. Dr. Pötter, who recently joined IQM, holds a PhD in physics and has extensive experience with digital technologies in the Aerospace and Cybersecurity industries. Dr. Pötter has held several international leadership positions with a focus on technology and innovation, among others at Airbus.

“I am excited to see IQM start its French operations in the Paris region, where I have been working for several years. The Paris team will build the bridge between the various IQM teams around Europe and the high-quality French quantum ecosystem. The team will enable local operations for collaborative IQM projects in strategic industrial areas,” said Dr. Pötter.

Speaking about this announcement, Dr. Jan Goetz, CEO and cofounder of IQM, said, “France plays an integral role in the quantum scientific research and has been on our roadmap for a while. I’m extremely pleased to announce the operations of our French entity today, especially at a time when the French quantum plan is gaining momentum. This French subsidiary together with our co-design teams in Bilbao and Munich and the quantum hardware and software teams in Espoo, Finland, will strengthen European quantum leadership.”

“The Paris region is proud to welcome a major European quantum computing player to the epicenter of the French quantum ecosystem. We support IQM’s local setup and growth to help them make the most of the excellent research and talent available. We are also convinced that IQM will thrive in France’s #1 aerospace region,” said Alexandra Dublanche, President of Choose Paris Region and Vice President in charge of Recovery, Attractiveness, Economic Development, and Innovation of the Paris Region.

“We are very thankful to Choose Paris Region and also Business France for the active, pragmatic, and timely support, which allowed us to set up IQM France in a very short time,” Dr. Pötter added.

In March 2021, Dr. Goetz presented on deep tech and building global tech leaders’ topics at the Scale-Up Europe event, where President Emmanuel Macron was an attendee. This presentation was part of the Scale-up Europe initiative facilitated by Sifted.

About IQM Quantum Computers:

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers the quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building a quantum computer in Germany that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich, and Espoo and employs over 130 people. More information: www.meetiqm.com

Links to the quoted press releases:

  • IQM opens its exclusive quantum fabrication facility in Finland
  • IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
  • IQM, as part of the Q-Exa consortium, is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.

Registered office:

IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland

Choose Paris Region is the agency in charge of promoting the attractiveness of the Paris region in terms of international business. The agency works in partnership with all the region’s key players to create an appealing and coherent territorial offer, ensure promotion of the region, and offer a tailor-made service to support international businesses and professionals in their expansion.

https://www.chooseparisregion.org/

Headquarters:

Choose Paris Region, 18 rue de Londres, 75009 Paris

contact@chooseparisregion.org - +33 800 019 011

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:

IQM Quantum Computers
Raghunath Koduvayur, Head of Marketing and Communications
Raghunath@meetiqm.com, +358 50 4876509

IQM France
Dr. Björn Pötter, Head of Product
Bjoern.Poetter@meetiqm.com, +49 171 649 6939

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye